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license (http://creativedisease (AD). We assessed retinal microvasculature in well-characterized AD cases, taking
ophthalmological confounders into account.
Methods: We included 48 amyloid-positive AD patients and 38 amyloid-negative cognitively
normal control subjects. All participants underwent ophthalmological screening to exclude
interfering ocular disease. Using a multimodal approach, we measured retinal vascular parameters,
choroidal thickness, macular vascular density, and foveal avascular zone size.
Results: We found no disease effects on retinal vascular measures (all b0s , j0.15j, all P . .2),
adjusted for confounders. Venular tortuosity was inversely associated with Fazekas score in control
subjects (b 20.56, P , .01), while vessel density in the outer ring of the macula was inversely
associated with Fazekas score in AD cases (b 20.64, P , .01).
Discussion: In conclusion, retinal vasculature did not discriminate patients with AD from control
subjects, despite evident changes on clinical, neuroimaging, and cerebrospinal fluid biomarkers,
challenging the use of retinal vasculature measurements as AD biomarker.
 2019 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Alzheimer’s disease (AD) pathophysiology is character-
ized by amyloid beta (Ab) accumulation, tau hyperphos-
phorylation, and neurodegeneration, ultimately leading to
cognitive decline [1]. In addition, vascular changes are
involved in AD pathophysiology. Vascular changes, either
intrinsic or as copathology, interact with AD pathology,thor. Tel: 131204440685; Fax: 131204448529.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).neurodegeneration, and cognitive impairment [2,3] and
are described with the term vascular cognitive
impairment (VCI) [4,5]. Vascular pathology is
prevalent and described at autopsy in up to 75% of
dementia cases [4,6]. Vascular changes include white
matter hyperintensities (WMHs) as a result of chronic
(subcortical) ischemia of small vessels, large vessel
infarcts, lacunar infarcts (e.g. thalamus), arteriosclerosis
and atherosclerosis, and cerebral amyloid angiopathy
(CAA) [7,8]. CAA is an intravascular pathology in which
Ab is deposited in the vessel wall and is associated with
microhemorrhages and microinfarcts [9]. Its prevalence isimer’s Association. This is an open access article under the CC BY-NC-ND
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in demented elderly in autopsy studies [9,10]. A strong
correlation between AD and CAA exists, as in
postmortem AD brains, in 85-95% of the cases CAA is
found [9]. Moreover, recent studies also showed that
decreased cerebral blood flow and blood-brain barrier
alterations might be involved in AD pathophysiology,
possibly playing a role in Ab clearance [2,3]. Currently
used biomarkers for vascular changes are limited
to magnetic resonance imaging (MRI) [8]. To better
understand and measure vascular changes in AD, new
biomarkers for vascular changes might increase
pathophysiological insight and could complement the
currently used ATN system for amyloid(A), tau(T), and
neurodegeneration(N) [11].
The retina is a possible source of vascular biomarkers as
retinal vasculature can be imaged noninvasively at the
micrometer level using different imaging modalities,
including fundus photography, measurements of choroidal
thickness (using enhanced depth imaging optical coherence
tomography (EDI-OCT) and OCT angiography (OCTA).
Vascular changes in the retina have been described in
AD, including changes in vascular parameters from fundus
photography analysis, using Singapore I Vessel analysis
(SIVA) software, such as increased venous diameter,
decreased arterial diameter, and decreased fractional
dimension [12]. In contrast, a recent report showed an
absence of group differences between AD patients and
control participants, while showing decreased total and
arteriolar fractal dimensions in VCI cases [13]. In addition,
choroidal thinning in AD is reported in several studies
using EDI-OCT [14–17]. Recent reports on retinal
vasculature with OCTA reported increased foveal
avascular zone (FAZ) size and decreased vessel density
and flow in AD [18,19] and preclinical AD [20].
As ophthalmological comorbidity could potentially
influence retinal vascular measurements and is often
asymptomatic, a thorough ophthalmological screening is
warranted. Second, assessing retinal biomarkers in patients
with a confirmed AD diagnosis by established biomarkers
such as cortical atrophy, amyloid and tau in cerebrospinal
fluid (CSF) or amyloid positron emission tomography
(PET) supports the clinical diagnosis on one hand and allows
comparison of the new biomarkers to the gold standard on
the other hand.
The aim of this study was to identify retinal vascular
biomarkers as possible noninvasive biomarkers in AD.
Following previous publications, we hypothesize to find
increased central retinal artery equivalent (CRAE),
decreased central retinal vein equivalent (CRVE), decreased
fractal dimension, thinner choroidal thickness, smaller
vessel density, and larger FAZ in AD compared to control
cases. We, therefore, measured retinal vascular parameters
using fundus photography, EDI-OCT, and OCTA in
well-characterized amyloid-positive AD cases, while taking
ophthalmological confounders into account. In addition, weassessed relationships between retinal vascular parameters
and WMHs on MRI.2. Methods
2.1. Subjects
We assessed 50 AD patients and 38 control subjects from
the Amsterdam Dementia Cohort (ADC) that were enrolled
into our retinal imaging cohort as described earlier (all
Mini-Mental State Examination (MMSE) 17, capable of
giving informed consent) [21]. In brief, all patients and
control subjects underwent a standardized screening
protocol including (medical) history, neuropsychological
examination, blood draw for apolipoprotein E ε4/ε4
(APOE ε4/ε4) genotype, blood pressure measurements,
neuroimaging, and lumbar puncture [22]. All patients met
National Institute on Aging and Alzheimer’s Association
criteria of AD and had evidence of amyloid pathology based
on CSF analysis or amyloid PET [11]. Controls were
subjects with cognitive complaints that showed no evidence
of objective cognitive impairment, neurodegeneration, or
amyloid pathology based on amyloid PET or CSF analysis.2.2. MRI scanning
MRI scans were reviewed by an experienced and blinded
rater (FB) before the multidisciplinary meeting of the ADC,
where a clinical diagnosis was made by consensus. Visual
rating scores for atrophy on MRI were determined based
on T1-weighted images and included medial temporal lobe
atrophy, global cortical atrophy, and parietal cortical atrophy
[23–25]. Vascular assessment included Fazekas score for
white matter hyperintensities (fluid attenuation inversion
recovery sequence), assessment of lacunar infarcts (fluid
attenuation inversion recovery, T2-weighted sequences),
and microbleeds (T2*-sequence) [26].2.3. Cerebrospinal fluid analysis
CSF was analyzed using Innotest ELISA and measured
amyloid-beta-1-42(Ab1-42), tau-181, and phosphorylated Tau
(pTau). A tau-181/Ab1-42 ratio .52 was considered an AD
profile [27].2.4. Amyloid PET analysis
A subset of cases was enrolled in research programs that
included amyloid PET scanning with the following tracers:
18F-Florbetaben (NeuraCeq) (n 5 24), 18F-Florbetapir
(Amyvid) (n 5 9), and Pittsburgh compound (11C-PIB)
(n 5 3). Parametric standardized uptake value images of
amyloid PET scans were assessed by an experienced rater
(BvB) and visually interpreted as amyloid positive or
amyloid negative following guidelines for individual tracers.
Fig. 1. Overview of retinal modalities to assess microvasculature. Retinal
vasculature was assessed using three imaging modalities: retinal vascular
parameter analysis using SIVA applied on fundus photographs (red), choroidal
thickness measurements using enhanced depth imaging optical coherence
tomography (EDI-OCT) (green), and vessel density and foveal avascular
zone (FAZ) measured with OCT angiography (OCTA) (yellow). Abbrevia-
tions: OCT, optical coherence tomography; SIVA, Singapore I Vessel analysis.
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Subjects were included within a year after the
ADC diagnostic screening program and underwent the
following eye examinations to exclude possible confounding
ophthalmological pathology: best-corrected visual acuity,
intraocular pressure using noncontact tonometry (if intraoc-
ular pressure .20 mmHg, we used contact applanation
tonometry), slit-lamp examination of the anterior and poste-
rior segment, Heidelberg retinal tomography optic nerve
head (ONH) analysis, and frequency doubling technology
for visual fields. Tropicamide (0.5%) was administrated
for pupil dilation to facilitate optimal ophthalmic examina-
tion. We followed the fourth European Glaucoma Guideline
criteria: glaucoma was diagnosed when two of the three
following measurements were abnormal: ocular pressure
(.21 mmHg), structural glaucomatous changes (examined
with Heidelberg retinal tomography using the Moorfields
regression analysis), and functional changes (examined
with frequency doubling technology) [28]. All examinations
were interpreted by an experienced ophthalmologist (FDV).
Exclusion criteria were ophthalmological conditions
interfering with imaging or retinal vasculature, such as
severe cataract, age-related macular degeneration, and
glaucoma or systemic conditions such as diabetes mellitus.2.6. Retinal vascular imaging
Retinal vasculature was measured by personnel blinded
for diagnosis, using three imaging modalities: (1) fundus
photography, (2) enhanced depth imaging OCT (EDI-OCT)
and (3) OCT angiography (OCTA) (Fig. 1). Digital fundus
images of 50 field of view of the macula and ONH were
obtained using a Topcon TRC 50DX type IA (Topcon
Medical Systems, Inc., Oakland, CA, USA). Macular
photographs were assessed for incident pathology by an
experienced ophthalmologist (FDV), whereas ONH
photographs were used for SIVA analyses (version 3.0;
National University of Singapore, Singapore) [29–31] by
two trained raters (JdH, JAvdK). Values from both eyes of
every participant were averaged; if only one suitable
image was present, only this eye was included (n 5 3). We
assessed vascular parameters that were earlier found to
have high intraobserver intraclass correlation (.0.80) [32],
namely CRAE, CRVE, arteriole-to-venule ratio, fractal
dimension of the arteriolar network (FDa), fractal dimension
of the venular network, curvature tortuosity of the arterioles
(cTORTa), and curvature tortuosity of the venules. We
averaged vascular parameters of two raters. Intraobserver
intraclass correlation coefficients of the present study are
shown in Supplementary Table 1.
EDI-OCT scans were acquired with a Heidelberg
Spectralis spectral domain-OCT, using the following
protocol: central retina (macula) fast horizontal scanning;
central 20 ! 20 area; 25 B-scans (averaging 9 frames
per b-scan); 512 a-scans per b-scan. Manual measurementsof choroidal thickness were performed in five evenly
distributed b-scans per macular volume scan
(Supplementary Fig. 1) [14,16,17]. Five measurements per
b-scan were performed: foveal, 1 mm nasal and temporal
from the fovea and 2 mm nasal and temporal from the
fovea. The anterior boundary of the choroid layer was
defined as the hyperreflective band corresponding to the
retinal pigment epithelium—Bruch’s membrane complex.
To define the posterior boundary, each measurement point
was categorized based on the presence or absence of the
choroidal-scleral interface as a hyperreflective band, the
suprachoroidal space as a hyporeflecting band, and/or a
smooth line marking the posterior boundary on the OCT
image. The posterior boundary was then defined as the outer
limit of the choroidal-scleral interface, the inner limit of the
suprachoroidal space, or the smooth line. If no clear
boundary was identifiable over the length of the scan, the
image was defined as ungradable. The averages of the
measurements (n 5 25) from both eyes were used for
analysis of mean choroidal thickness.
OCTA was acquired using a Zeiss Model 5000 spectral
domain-OCT with Angioplex and consisted of 6 ! 6 mm
scans of the macula, 350 b-scans each. Vascular density
measured in the inner ring (Ø 1-3 mm around fovea) and
outer ring (Ø 3-6 mm around fovea) of the Early Treatment
in Diabetes Retinopathy Study grid. FAZ surface area
was measured. Scans were visually assessed for quality.
All scans had quality factors7/10 and could be considered
“good” quality.
Table 1
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Cohort characteristics
Alzheimer’s
disease Controls P value
Number 48 38
Sex (m/f) 25/23 24/14 .24*
Age 65.4 (68.1) 60.6 (65.0) ,.01y
MMSE 23 (63) 29 (61) ,.01y
Body mass index (kg/m2) 24.4 (63.1) 26.2 (64.1) .32y
APOE ε4/ε4 genotypex
E4 homozygous, n (%) 11 (23.4) 1 (2.9) ,.01*
E4 heterozygous, n (%) 22 (46.8) 9 (26.5) .05*
E4 negative, n (%) 14 (29.8) 24 (70.6) ,.01*
Blood pressure measures
Systolic blood pressure
(mmHg)
148.9 (617.5) 139.0 (618.4) .02y
Diastolic blood
pressure (mmHg)
84.2 (610.1) 82.8 (69.1) .55y
Pulse pressure (mmHg) 64.7 (612.6) 56.2 (612.5) ,.01y
Mean arterial pressure
(mmHg)
84.4 (664.1) 59.3 (683.5) .01y
MRI#
Global cortical atrophy
(GCA)
1 (0-2) 0 (0-1) ,.01y
Medial temporal lobe
atrophy (MTA)
1.5 (0-2.5) 0 (0-2) ,.01y
Parietal cortical atrophy
(PCA)
1 (0-3) 0 (0-1) ,.01y
Fazekas score 1 (0-3) 1 (0-2) .08z
Microbleeds (n) 0.1 (60.4) 2.7 (614.6) .35z
Lacunar infarcts (n) 0 (60) 0.2 (60.6) .02z
CSF{
Ab1242 (ng/L) 555.1 (6106.2) 1162.3 (6200.0) ,.01
z
Tau-181 (ng/L) 711.5 (6304.5) 242.2 (685.7) ,.01
z
pTau (ng/L) 89.0 (628.3) 43.0 (611.8) ,.01z
Tau-181/Ab1-42 ratio 1.3 (60.5) 0.2 (60.1) ,.01
z
Ab PET**
Positive/negative 17/0 0/19 ,.01z
Ophthalmological
Intraocular pressure
(mmHg)
16.3 (62.3) 16.0 (62.1) .39z
Visual acuity
(LogMAR)
0.0 (60.1) 20.1 (0.1) ,.01z
Significant associations (P ,.05) are displayed in bold.
Abbreviations: APOE, apolipoprotein E; Ab, amyloid beta; CSF,
cerebrospinal fluid; MMSE, Mini-Mental State Examination; MRI,
magnetic resonance imaging; PET, positron emission tomography.2.7.1. Power calculation
Based on a previous meta-analysis [12], comparing
374 AD cases compared to 707 control subjects, a decrease
of 7.52 mm in CRAE can be expected. Assuming a true effect
of 7.52 mm and a standard deviation ofz15 mm, 28 subjects
in each group are needed to reject the null hypothesis of no
difference between the disease and control group with a
power of 0.80. In addition, from the same meta-analysis a
decrease of 10.74 mm in CRVE can be expected. Assuming
a true effect of 10.74 mm and a standard deviation of
z15 mm, 15 subjects in each group are needed to reject
the null hypothesis of no difference between the disease
and control group with a power of 0.80. From a
previous report [16], a decrease of z60 mm in choroidal
thickness can be expected. Assuming a true effect of
60 mm and a standard deviation of z50 mm, 6 subjects in
each group are needed to reject the null hypothesis of no
difference between the disease and control group with a
power of 0.80. We included .35 participants per disease
group.
2.7.2. Data analysis
Data were visually tested for a normal distribution
using histograms and Q-Q plots. Measures that were
normally distributed were tested with an independent
t-test, nonnormally distributed measures with a
Mann-Whitney U test, and binary variables with a
chi-squared test. Linear regression models were used to
assess if changes in retinal vasculature (dependent) were
attributable to diagnosis (independent) or age, sex,
spherical equivalent, quality factor, and/or hypertension
(covariates). All betas reported are standardized betas.
Stratified analysis for APOE ε4/ε4 genotype carriers
versus noncarriers was performed for retinal vascular
parameters. Intraobserver intraclass correlation (absolute
agreement) was calculated to test intrarater variability for
SIVA. Data analysis was performed with IBM SPSS
Statistics (version 22.0).*Chi-square test.
yIndependent samples t-test.
zMann-Whitney U test.
xAPOE ε4/ε4 genotype was available in 47 AD cases and 34 control
subjects.
{MRI was available in 47 AD cases and 35 control subjects.
#CSF was available in 46 AD cases and 29 control subjects.
**Amyloid PET was available in 17 AD cases and 19 control
subjects.3. Results
Table 1 shows cohort characteristics. We included 50 AD
patients and 38 control subjects from our retinal imaging
[21] cohort with retinal vasculature imaging available. One
AD case was excluded because of glaucoma. In addition,
we excluded one AD case that was later found to have a
progranulin mutation, a mutation known to directly affect
retinal integrity [33]. As a result, fundus photographs were
available in 48 AD patients and 38 control participants.
EDI-OCT and OCTA became available in the course of the
study and were obtained in 41 AD patients and 31 control
participants for EDI-OCTand 26 AD patients and 31 control
participants for OCTA. AD cases were slightly older (65.4 yvs. 60.6 y, P, .01) and had MMSE and MRI atrophy scores
indicative of an AD diagnosis. There was no difference
between groups for WMH and lacunes indicating similar
cerebrovascular loading. By design, all AD cases were
amyloid positive and all control participants were amyloid
negative based on CSF (n 5 50), amyloid PET (n 5 11),
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more prevalent in AD cases (70.2% vs. 29.4% in control
subjects) [34]. Systolic blood pressure, pulse pressure, and
mean arterial pressure were higher in control subjects
(independent t-test, P 5 .02, P , .01, and P 5 .01,
respectively).
3.1. Retinal vasculature parameters3.1.1. Singapore I Vessel analysis (SIVA)
Seven retinal vascular parameters, previously shown
to have good reproducibility [32], showed no
group differences between AD patients and control
participants (Fig. 2A). Linear regression models assessing
relationships between retinal vascular parameters and
diagnosis, adjusted for age, and spherical equivalent
(SE), showed no disease effect (Table 2). CRVE and
FDa were found to be associated with age (b 20.25,
P 5 .03 and b 20.28, P 5 .02, respectively) (Table 2).
Adjusting analysis for systolic blood pressure, pulse
pressure, or mean arterial pressure did not alter disease
effects.
3.1.2. Choroidal thickness analysis
Choroidal thickness in the macula showed no group
differences between AD patients (246.4 mm, 682.0) and
control participants (251.3 mm, 668.6) (independent t-test,
P 5 .588) (Fig. 2B). Linear regression models assessing
relationships between choroidal thickness and diagnosis,
adjusted for age, and SE showed no disease effect (b 0.14,
P 5 .24) but was associated with age (b 20.34, P 5 .01)
and SE (b 0.43, P 5 .01) (Table 2). Adjusting analysis for
different measures of blood pressure did not alter AD disease
effects.
3.1.3. OCTA analysis
Vessel density in the inner and outer ring of the macula
and the size of the FAZ showed no group differences
between AD patients and control participants (Fig. 2C).
Linear regression models assessing relationships between
OCTA measures and diagnosis, adjusted for age, SE, and
quality factor, showed no disease effect for vessel density
in the inner ring (b 0.02, P 5 .85) or outer ring (b 20.10,
P 5 .36), or FAZ (b 20.14, P 5 .33). Vessel density was,
however, strongly associated with quality factor (inner ring
[b 0.77, P , .001], outer ring [b 0.65, P , .001]), unlike
FAZ (b 20.04, P 5 .81) (Table 2). Adjusting analysis for
different measures of blood pressure did not alter AD disease
effects.
3.2. Relationships between retinal vascular parameters
and white matter hyperintensities
To assess relationships between retinal vasculature and
intracerebral vascular changes, we correlated retinal
vascular parameters with WMH scores on MRI (Fazekasscore), adjusting for age and sex. Vessel density in the outer
ring was found to be inversely associated with Fazekas score
in AD participants (b 20.64, P , .01), while curvature
tortuosity of veins was inversely associated with Fazekas
score in control subjects (b20.56, P, .01). No associations
were found between other retinal vascular parameters and
WMH scores (Table 3).
3.3. Relationships between retinal vascular parameters
and MMSE, CSFAb1-42, and APOE ε4/ε4 genotype
Both adjusted and unadjusted for age and sex, no
relationships between retinal vascular parameters and MMSE
or CSF Ab1-42 were observed. Comparing APOE ε4/ε4
carriers (n 5 44) versus noncarriers (n 5 37), irrespective of
diagnosis, no differences in retinal vascular measures were
found (independent samples t-test, all P . .16).
3.4. Stratified analyses for early- versus late-onset
Alzheimer’s disease
Stratifying analyses of retinal vascular parameters,
choroidal thickness, and OCTA measures for early- versus
late-onset AD showed no group differences between the
two disease group and controls, or between disease groups.4. Discussion
In this cross-sectional study using three imaging
modalities, we found that there were no group differences
in retinal vasculature between well-phenotyped, amyloid
confirmed, AD and control cases after correction for age
and sex. Stratifying cases for early- versus late-onset AD
yielded similar results. Vessel density in the outer ring of
the macula was found to be associated with WMH scores
on MRI in AD participants, while curvature tortuosity
of veins was associated with WMH scores in control
subjects.
Our findings of unaltered retinal vascular caliber
parameters on fundus photography in AD confirm a recent
study that included biomarker confirmed AD cases
(n 5 29) based on amyloid PET imaging [13]. In that
same study, decreased FDa was observed in subcortical
VCI patients [13]. In contrast, other studies found
differences in various retinal vascular parameters in different
directions, that include decreased CRVE [35,36], CRAE
[36], fractal dimension of the venular network [35–37],
FDa [35], cTORTa [37] and increased cTORTa [35], and
curvature tortuosity of the venules [35] in AD patients
compared to control participants. As these cohorts were
larger (n . 100 per patient group), it might indicate that
the effect size of retinal vascular parameters is small and
possibly remained undetected in our study. Alternatively,
as previous studies used clinical diagnosis, cohorts could
have consisted of dementia cases with a primarily vascular
etiology or of cases with relevant vascular copathology. In
those cases, retinal (micro)vasculature changes may
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Table 2
Associations of vascular parameters with diagnosis, age, spherical equivalent, and quality factor
Retinal vasculature parameter
Mean (SD) Age SE AD Quality factor
AD Controls b P value b P value b P value b P value
SIVA
CRAE 106.1 (67.5) 107.9 (612.1) 20.12 .32 0.16 .17 20.08 .49 n.a. n.a.
CRVE 161.6 (612.2) 168.1 (615.6) 20.25 .03 0.19 .08 20.13 .27 n.a. n.a.
AVR 0.66 (60.05) 0.64 (60.06) 0.13 .27 20.03 .78 0.05 .68 n.a. n.a.
FDa 1.16 (60.04) 1.17 (60.04) 20.28 .02 0.15 .17 20.05 .68 n.a. n.a.
FDv 1.15 (60.04) 1.15 (60.04) 20.15 .21 20.02 .83 0.14 .23 n.a. n.a.
cTORTa* 8.1 (61.5) 8.7 (61.9) 20.05 .69 0.04 .74 20.15 .22 n.a. n.a.
cTORTv* 8.5 (61.7) 8.4 (61.2) 20.05 .66 0.09 .41 0.06 .61 n.a. n.a.
EDI-OCT
Choroidal thickness (mm) 246.4 (682.0) 251.3 (668.6) 20.34 ,.01 0.43 ,.01 0.14 .24 n.a. n.a.
OCTA
Vessel density inner ring 17.3 (61.5) 17.4 (61.2) 0.07 .49 0.08 .37 0.02 .85 0.77 ,.01
Vessel density outer ring 17.4 (61.3) 17.8 (61.1) 20.07 .50 0.16 .11 20.10 .36 0.65 ,.01
Foveal avascular zone (mm2) 0.24 (60.06) 0.26 (60.08) 0.04 .81 0.07 .60 20.14 .33 20.04 .81
Associations between vascular parameters, age, spherical equivalent, AD diagnosis, and quality factor from linear regression models. Means and standard
deviations and uncorrected P values are given. Significant associations (P ,.05) are displayed in bold.
Abbreviations: AD, Alzheimer’s disease; AVR, arteriole-to-venule ratio; b, standardized beta; CRAE, central retinal artery equivalent; CRVE, central retinal
vein equivalent; cTORTa, curvature tortuosity of the arterioles; cTORTv, curvature tortuosity of the venules; EDI-OCT, enhanced depth imaging optical
coherence tomography; FDa, fractal dimension of the arteriolar network; FDv, fractal dimension of the venular network; n.a., not applicable; OCTA, optical
coherence tomography angiography; SD, standard deviation; SE, spherical equivalent; SIVA, Singapore I Vessel analysis.
*Values *1025.
=
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changes. In the current cohort of amyloid-proven AD
participants, clinical, neuroimaging, and fluid biomarkers
showed clear disease effects, while an intrinsic AD effect
on retinal vasculature was not detected. This queries the
clinical use of retinal vascular caliber measurements as
AD biomarker.
Using EDI-OCT, we did not observe choroidal thinning
as previously described by a number of studies [14–17],
despite comparable group size and methodology. Not all
studies adjusted their analyses for confounders such as age
and spherical equivalent, which could have influenced
reported findings, as these confounders showed significant
effects on choroidal thickness in the present study
contributing to choroidal thinning. Both uncorrected and
corrected for age, we found no group differences in
choroidal thickness. In addition, as our study did not
directly take measurement time point into account, we
were not able to control for known diurnal variation of
choroidal thickness, that could have possibly influenced
our findings, as variation in the order of 15-33 mm are
observed over 24 hours [38–40]. However, distribution of
measurement time over the day was comparable between
groups in our study, with a mean around midday in both
groups.Fig. 2. Vascular parameters measured with fundus photography, EDI-OCT and O
(SIVA) software included central retinal artery equivalent (CRAE), central retinal
the arteriolar network (FDa), fractal dimension of the venular network (FDv), cu
tortuosity of the venules (cTORTv, values *1025), compared between Alzheimer’s
measured in the macula (mm) in AD. (C) Vascular parameters from optical cohere
ring of the Early Treatment in Diabetes Retinopathy Study grid and surface are
participants. Abbreviation: AD, Alzheimer’s disease.In this study, describing OCTA measurements in
amyloid-positive AD cases for the first time, we found no
differences in vessel density and FAZ, while a strong effect
of quality factor (QF) on vessel density measurements was
observed [b . 0.65, P , .001] in scans with acceptable QFs
(between 7 and 10). In contrast, previous studies described a
decrease in vessel density and an increase in FAZ surface
area in (preclinical) AD cases [18–20]. However, as
ophthalmological confounders, age, SE, and QF were not
always taken into account, findings of those studies may
represent an overestimation of true disease effects.
Given the thorough characterization of our participants,
we were able to correlate retinal vascular measurements
with WMH on MRI, Ab1-42, Tau-181, and pTau in CSF and
MMSE. Venular tortuosity was inversely correlated with
WMH scores on MRI in control subjects, while in contrast
an earlier study reported a positive correlation between
WMH and venular tortuosity in control subjects [32].
Confirming an earlier report, we found an inverse
association between macular vessel density and WMH
scores in AD, possibly reflecting microvasculature changes
in chronic cerebral microinfarction. Similarly, in a recent
report, a relation between WMH volume and fractal
dimension was observed [13]. These findings need
confirmation in larger cohorts, including volumetricCTA. (A) Vascular parameters calculated using Singapore I Vessel Analysis
vein equivalent (CRVE), arteriole–venule ratio (AVR), fractal dimension of
rvature tortuosity of the arterioles (cTORTa, values *1025), and curvature
disease participants (AD) and controls (HC). (B) Mean choroidal thickness
nce tomography angiography (OCTA). Vessel density in the inner and outer
a (mm2) of the foveal avascular zone, compared between AD and control
Table 3
Association between vascular parameters andWMHs in the total cohort and
stratified for diagnosis, adjusted for age and sex
Retinal vasculature
parameter
White matter hyperintensities (Fazekas score)
Total AD Controls
b P value b P value b P value
SIVA
CRAE 0.03 .83 20.05 .79 0.01 .98
CRVE 20.06 .560 20.09 .57 20.06 .74
AVR 0.07 .57 0.01 .97 0.09 .61
FDa 20.11 .40 20.12 .48 20.14 .47
FDv 20.01 .94 0.02 .92 20.21 .29
cTORTa* 0.06 .65 0.27 .12 20.29 .14
cTORTv* 20.11 .40 0.10 .57 20.56 ,.01
EDI-OCT
Choroidal
thickness (mm)
20.07 .58 20.06 .72 0.02 .92
OCTA
Vessel density
inner ring
20.29 .09 20.48 .05 20.01 .98
Vessel density
outer ring
20.32 ,.05 20.64 ,.01 0.18 .40
Foveal avascular
zone (mm2)
20.18 .29 20.11 .61 20.08 .69
Associations between vascular parameters and WMHs (Fazekas score)
were assessed using linear regression, adjusted for age and sex.
Standardized betas and uncorrected P values are given. Significant
associations are indicated in bold.
Abbreviations: AD, Alzheimer’s disease; AVR, arteriole-to-venule ratio;
b, standardized beta; CRAE, central retinal artery equivalent; CRVE, central
retinal vein equivalent; cTORTa, curvature tortuosity of the arterioles;
cTORTv, curvature tortuosity of the venules; EDI-OCT, enhanced depth
imaging optical coherence tomography; FDa, fractal dimension of the
arteriolar network; FDv, fractal dimension of the venular network;
OCTA, optical coherence tomography angiography; SIVA, Singapore I
Vessel analysis.
*Values *1025.
J.den Haan et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 (2019) 383-391390measures of WMHs. We found no associations between
retinal vascular parameters and CSF biomarkers or MMSE.
A limitation of our study is its relatively small sample size
and incomplete collection of all vascular markers,
hampering sensitivity for small diseases effects on
retinal vasculature. However, despite its relevance for
understanding involvement of retinal vasculature in AD
pathophysiology, the added value of these small effects for
clinical use as a biomarker remain doubtful. As our cohort
consisted of cases with relatively little vascular comorbidity,
studies in VCI and mixed pathology are warranted to assess
the use of retinal vascular parameters to detect vascular
(co)-pathology in these populations.
5. Conclusion
Using a multimodal retinal imaging approach in well-
characterized amyloid status–confirmed AD and control
cases, we found no evidence that retinal vasculature can be
used as a noninvasive biomarker for AD.Acknowledgments
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1. Systematic Review: The authors searched PubMed
for all publications assessing retinal microvascula-
ture in Alzheimer’s disease (AD). Well-phenotyped
cohorts including amyloid status, white matter
hyperintensities on magnetic resonance imaging and
ophthalmological screening have not previously
been examined.
2. Interpretation: In this study, representing the largest
cohort with amyloid proven AD cases, we show
that retinal vasculature does not discriminate AD
from control participants, despite evident changes
on clinical, neuroimaging, and cerebrospinal fluid
measures, querying the use of retinal vasculature
measurements as AD biomarker.
3. Future directions: Future studies in cases with
vascular cognitive impairment and mixed pathology
are needed to assess the role of retinal vasculature as
noninvasive biomarker for vascular (co)-pathology.References
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